Serotonin enhances oxybuprocaine- and proxymetacaine-induced cutaneous analgesia in rats

An Kuo Chou, Chong Chi Chiu, Jhi Joung Wang, Yu Wen Chen, Ching Hsia Hung

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)


The aim of the study was to investigate the analgesic effects of adding serotonin to oxybuprocaine or proxymetacaine preparations. We employed a rat model of the cutaneous trunci muscle reflex (CTMR) to conduct the dose-response curves and duration of drugs (oxybuprocaine, proxymetacaine, or serotonin) as an infiltrative anesthetic. The use of isobolographic methods to analyze the drug-drug interactions. We showed that oxybuprocaine and proxymetacaine, as well as serotonin produced dose-dependent skin antinociception. On the basis of 50% effective dose (ED50), the rank order of drug potency was serotonin [7.22 (6.45–8.09) μmol/kg] < oxybuprocaine [1.03 (0.93–1.15) μmol/kg] < proxymetacaine [0.59 (0.53–0.66) μmol/kg] (P < 0.01 for each comparison). The sensory block duration of serotonin was longer (P < 0.01) than that of oxybuprocaine or proxymetacaine at the equipotent doses (ED25, ED50, and ED75). The mixture of serotonin with oxybuprocaine or proxymetacaine produced a better analgesic effect than the drug itself. We have concluded that oxybuprocaine, proxymetacaine, or serotonin displays dose-related cutaneous analgesia. Oxybuprocaine or proxymetacaine is more potent and has a shorter duration of cutaneous analgesia than serotonin. Serotonin produces a synergistic antinociceptive interaction with oxybuprocaine or proxymetacaine.

Original languageEnglish
Pages (from-to)73-78
Number of pages6
JournalEuropean Journal of Pharmacology
Publication statusPublished - 2019 Mar 5

All Science Journal Classification (ASJC) codes

  • Pharmacology


Dive into the research topics of 'Serotonin enhances oxybuprocaine- and proxymetacaine-induced cutaneous analgesia in rats'. Together they form a unique fingerprint.

Cite this